Effect of Botulinum Toxin Type A on Nasal Symptoms in Patients with Allergic Rhinitis: A Double-blind, Placebo-controlled Clinical Trial

Acta Oto-Laryngologica

Volumn 123, Issue 9, 2003, Pages 1060-1063

  Ünal, Murat ^a,b   Sevim, Serhan ^a   Doǧu, Okan ^a   Vayisoǧlu, Yusuf ^a   Kanik, Arzu ^a  

^a MERSIN UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b MERSIN UNIVERSITY   (Turkey)

Author keywords

Botulinum toxin; Nasal allergy; Rhinitis; Rhinorrhea

Indexed keywords

BOTULINUM TOXIN A; PLACEBO; SODIUM CHLORIDE;

ADULT; ALLERGIC RHINITIS; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; MALE; NOSE CAVITY; NOSE OBSTRUCTION; PRICK TEST; PRIORITY JOURNAL; PRURITUS; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RHINORRHEA; SCORING SYSTEM; SKIN TEST; SNEEZING; TREATMENT OUTCOME;

EID: 9144246164     PISSN: 00016489     EISSN: None     Source Type: Journal    
DOI: 10.1080/00016489.2003.11720744     Document Type: Article

References (15)

1. Skoner DP. Allergic rhinitis: definition, epidemiology, pathophysiology, detection and diagnosis. J Allergy Clin Immunol 2001; 108: S2-8.
2. Aberg N. Asthma and allergic rhinitis in Swedish conscripts. Clin Exp Allergy 1989; 19: 59-63.
3. Shaari CM, Sanders I, Wu BL, Biller HF. Rhinorrhea is decreased in dogs after nasal application of botulinum toxin. Otolaryngol Head Neck Surg 1995; 112: 566-71.
4. Holmberg K, Bake B, Pipkorn U. Reflex activation in allergen-induced nasal mucosal vascular reactions. Acta Otolaryngol (Stockh) 1989; 108: 130-5.
5. Schantz EJ, Johnson EA. Properties and uses of botulinum toxin and other microbial neurotoxins in medicine. Microbiol Rev 1992; 56: 80-99.
6. Jankovic J, Brin MF. Therapeutic uses of botulinum toxin. N Engl J Med 1991; 324: 1186-94.
7. Drobik C, Laskawi R. Frey's syndrome: treatment with botulinum toxin. Acta Otolaryngol (Stockh) 1995; 115: 459-61.
8. Koriwchak MJ, Netterville JL, Snowden T, Courey M, Ossoff RH. Alternating unilateral botulinum toxin type A (BOTOX) injections for spasmodic dysphonia. Laryngoscope 1996; 106: 1476-81.
9. Lee MC. Spasmodic torticollis: medical and botulinum toxin A treatment. Yonsei Med J 1992; 33: 289-93.
10. Kim KS, Kim SS, Yoon JH, Han JW. The effect of botulinum toxin type A injection for intrinsic rhinitis. J Laryngol Otol 1998; 112: 248-51.
11. Rohrbach S, Laskawi R. Minimally invasive application of botulinum toxin type A in nasal hypersecretion. ORL J Otorhinolaryngol Relat Spec 2001; 63: 382-4.
12. Rohrbach S, Olthoff A, Laskawi R, Giefer B, Götz W. Botulinum toxin type A induces apoptosis in nasal glands of guinea pigs. Ann Otol Rhinol Laryngol 2001; 110: 1045-50.
13. Scott AB, Suzuki D. Systemic toxicity of botulinum toxin by intramuscular injection in the monkey. Mov Disord 1988; 3: 333-5.
14. Mygind N. Mediators of nasal allergy. J Allergy Clin Immunol 1982; 70: 149-59.
15. Borodic GE, Ferrante RJ, Pearce LB, Alderson K. Pharmacology and histology of the therapeutic application of botulinum toxin. In: Jankovic J, Hallett M, eds. Therapy with botulinum toxin. New York: Marcel Dekker, 1994: 119-59.